DexCom, Inc. $DXCM Stake Cut by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,757 shares of the medical device company’s stock after selling 481 shares during the period. Mutual of America Capital Management LLC’s holdings in DexCom were worth $4,256,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Horizon Investments LLC lifted its position in shares of DexCom by 2.2% in the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock worth $383,000 after purchasing an additional 123 shares in the last quarter. Wedbush Securities Inc. lifted its position in DexCom by 1.2% in the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock worth $899,000 after buying an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. lifted its position in DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock worth $407,000 after buying an additional 182 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its position in DexCom by 3.2% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after buying an additional 187 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 1.4%

Shares of DXCM stock opened at $70.70 on Thursday. The stock’s 50 day simple moving average is $72.76 and its 200 day simple moving average is $77.65. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a market capitalization of $27.73 billion, a price-to-earnings ratio of 49.10, a PEG ratio of 1.46 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business earned $0.43 EPS. The firm’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on DXCM. Argus began coverage on DexCom in a report on Thursday, August 21st. They set a “buy” rating and a $100.00 price objective for the company. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.40.

Insider Activity

In other news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,849 shares of company stock worth $564,733. Insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.